Navigation Links
Repligen Reports Second Quarter Fiscal Year 2011 Financial Results
Date:11/2/2010

d benefit from RG1068, a potential market opportunity of over $100 million.

RG2417 for Bipolar Disorder We have completed enrollment in our Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. The study enrolled 175 patients at 29 clinical sites within the United States.  The primary objective of the Phase 2b study is to assess the efficacy of RG2417 on the symptoms of bipolar depression by demonstrating a greater improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) score of the patients receiving RG2417 when compared to placebo over an 8-week treatment period.  MADRS is a standardized, rater-administered scale, which has been used for numerous drug trials in bipolar disorder.  In addition, the study will assess the safety of RG2417 in patients with bipolar depression including, lack of induction of mania as measured by the Young's Mania Rating Scale.  Additional secondary and exploratory objectives include improvements in the Clinical Global Impression scale, difference in MADRS scores after 8 weeks of therapy, and responder rate as defined as percent of patients with an improvement in MADRS score of greater than 50% from baseline to week 8.  We expect to report top-line results of the Phase 2b study in the first quarter of 2011.  

This study is designed to confirm and extend the results of a Phase 2a study in which 6 weeks of treatment with RG2417 improved the symptoms of bipolar depression when compared to placebo as measured by the MADRS.  In the Phase 2a study, a lower placebo effect was observed in those patients with more numerous episodes of mania and depression experienced during their lifetime resulting in a higher apparent therapeutic effect of RG2417, which will also be assessed in the Phase 2b study.

Bipolar disorder is a chronic illness associated with substantial morbidity and mortality, ranking worldwide behind unipolar depre
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
4. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
7. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
8. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
9. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
10. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
11. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 Hussey Copper , ... 29 antimicrobial copper announces Pullman Regional Hospital,s conversion ... EPA-registered antimicrobial solid touch surface, at a nominal cost.  ... MRSA, E-coli and other bacteria within 2 hours of exposure ... against bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... Mass. , July 22, 2014  The ... $650 million from philanthropist Ted Stanley ... and bringing new treatments based on molecular understanding ... world. The Stanley commitment – ... the largest for scientific research in general – ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Holomic ... with the debut of its fluorescent immunoassay reader, ... Chemistry (AACC) meeting in Chicago, July 28-31, 2014. ... top versions, the HRDR-300 is a highly sensitive, ... to analyze fluorescent lateral flow immunoassays with high ...
(Date:7/22/2014)... The next session of Clinovo’s ... will comprise of the increasingly popular ‘Base SAS’ and ... a series of technical hands-on classes for entry-level to ... the next step in their professional careers. , The ... Jennifer Kang, Senior Statistician at Genentech and former Senior ...
Breaking Biology Technology:Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3
... of electrospinning for applications primarily within the medical device ... announces a new technology platform in the field of ... ranging from the nano to microscale. Zeus is able ... and bioabsorbables. The result is a broad range of ...
... Zeus is slated to manufacture parts and assemble MOD® units, an ... ... Orangeburg, SC (PRWEB) February 15, 2009 -- Zeus, Inc., a ... pleased to announce a new partnership with Avancen MOD Corporation. ...
... free webinars providing continuing education for Chemists and Chemical Engineers. Visit ... as a listing of over sixty On-Demand Webinars. For your convenience, the ... , ... Columbia, MD (PRWEB) February 14, 2009 -- Each free ...
Cached Biology Technology:Electrospinning: Emerging New Technology at Zeus 2Zeus Partners with Avancen MOD Corp. 2Free Webinars in Chemistry and Chemical Engineering 2
(Date:7/22/2014)... will hear that drinking milk helps make their bones strong or ... foster the idea that if something is good for us, it ... Journal of Consumer Research , when children hear about the ... "We predicted that when food is presented to children as making ... as learning how to read or count, they would conclude the ...
(Date:7/22/2014)... and Shenzhen, China July 22, 2014 ... subsidiary of BGI, the world,s largest genomics organization, ... human whole exome sequencing service based on Complete ... in-depth bioinformatics analysis and SNP validation, and is ... , Complete Genomics, highly regarded in the ...
(Date:7/22/2014)... -- Nancy Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant ... Center New Orleans School of Nursing, contributed samples ... genetic material associated with schizophrenia and also suggesting ... schizophrenia. The study, Biological insights from 108 schizophrenia-associated ... in Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... a growing body of evidence that continued smoking after a ... survival, risk of other cancers, and quality of life, up ... so or relapse after trying to quit. , The ... a peer-reviewed journal of the American Cancer Society, says smoking ...
... GI infections in families with children in day careUsing an ... infections in the home, according to a study in the ... Greater Boston families -- half of which were given hand ... percent reduction in the spread of GI illnesses. , ...
... how the inhaled form of anthrax disarms bacteria-fighting white blood ... most victims within days. , The lethal toxin in anthrax ... body's first defense against infection, by impairing how they build ... body and eat invading bacteria. , Just two hours of ...
Cached Biology News:Many smokers fail to quit after cancer diagnosis 2Hand sanitizer gel works 2Anthrax stops body from fighting back, study shows 2Anthrax stops body from fighting back, study shows 3
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,669-3) ... assistance. ID clarifier: barcoded Mfr ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
... Freedom EVO96R and Freedom EVO384R are fast ... available in three different sizes, with a ... They deliver significant time saving, with true ... easy setup of your assays with the ...
Request Info...
Biology Products: